首页> 外文期刊>The Internet Journal of Pharmacology >Design, In Vitro Evaluation and Release Rate Kinetics of Matrix Type Sustained Release Tablet Containing Aceclofenac
【24h】

Design, In Vitro Evaluation and Release Rate Kinetics of Matrix Type Sustained Release Tablet Containing Aceclofenac

机译:含醋氯芬酸的基质型缓释片的设计,体外评价和释放速率动力学

获取原文
获取外文期刊封面目录资料

摘要

Enteric coated aceclofenac matrix tablets were formulated as sustained release tablets employing hydroxypropyl methylcellulose polymer and the sustained release behavior of the fabricated tablets were investigated. Sustained release matrix tablets containing 200 mg aceclofenac were developed using different drug polymer ratios of hydroxypropyl methylcellulose. Tablets were prepared by wet granulation technique. Formulation was optimized on the basis of acceptable tablet properties and in vitro drug release. The resulting formulations produced monolithic tablets with optimum hardness, uniform thickness, consistent weight uniformity and low friability. Aceclofenac release from tablets was extended from 16 to 24 h from formulated batches. The results of dissolution studies indicated that formulation F-V (drug to polymer 1:0.470), the most successful of the study, exhibited drug release pattern very close to theoretical release profile. Applying kinetic equation models to F-V batch it was found to be followed Higuchi model, as the plots showed high linearity, with correlation coefficient (R2) value 0.9911.Therefore, the formulation F-V tablets showed diffusion dominated drug release. The accelerated stability study showed that the shelf life 40 months (batch F-V) and promising drug storage results. Introduction Aceclofenac, a phenylacetic acid derivative, is a non-steroidal anti-inflammatory drug (NSAID) related to diclofenac. It is used in the management of osteoarthritis, rheumatoid arthritis and alkylosing spondylitis (1). Through its analgesic and anti-inflammatory properties, aceclofenac provides symptomatic relief in a variety of painful conditions. Aceclofenac is well tolerated, with most adverse effects being minor and reversible, affecting mainly gastrointestinal system (2). It is well absorbed from gastrointestinal tract and peak plasma concentrations (Cmax) are reached 1-3 h after oral dose. The short biological half life (approximately 4.3 h) and the need for long duration favour development of a sustained release formulation. Sustained release tablets can offer advantages like limiting fluctuation within the therapeutic range, decreasing dosage frequency and improving patient compliance.The simplest way to retard drug release is to disperse it in a solid matrix. The matrix system is commonly used for manufacturing sustained release dosage forms especially tablets because it makes such manufacturing easy. Hydrophilic matrices are an interesting option when formulating an oral sustained release (SR) of a drug. The dosage release properties of matrix devices may be dependent upon the solubility of the drug in the polymer matrix or, in case of porous matrices, the solubility in the sink solution within the particle’s pore network (3). Hydroxypropyl methylcellulose (HPMC) is the dominant hydrophilic vehicle used for the preparation of oral controlled drug delivery systems (4). Numerous studies have been reported in literature investigating the HPMC matrices to control the release of a variety of drugs from matrices and trying to predict drug release kinetic models (5-9). According to most of these models, diffusion is thought to occur in release of drugs and anomalous release due to effect of excipients in matrices. One of the common complaints of oral NSAID including aceclofenac is gastric irritation associated with their use. Therefore enteric coated aceclofenac tablets are interesting option to circumvent this problem of GI irritation.The objective of the study was to prepare enteric coated sustained release aceclofenac tablets using HPMC matrix, to examine the in vitro release characteristics, to predict the release behavior of aceclofenac from the matrix and to elucidate shelf life of the fabricated formulation. In order to elucidate release kinetics it is necessary to fit drug release data into a suitable model. The commonly adopted models for understanding the release of drugs from hydrophilic matrices are first-ord
机译:肠溶性醋氯芬酸基质片剂被制成使用羟丙基甲基纤维素聚合物的缓释片剂,并研究了制得的片剂的缓释行为。使用羟丙基甲基纤维素的不同药物聚合物比例开发了含有200毫克醋氯芬酸的缓释基质片剂。通过湿法制粒技术制备片剂。基于可接受的片剂性质和体外药物释放来优化制剂。所得制剂产生具有最佳硬度,均匀厚度,一致的重量均匀性和低脆性的整体式片剂。片剂中醋氯芬酸的释放从配制批次延长了16到24小时。溶出度研究的结果表明,最成功的制剂F-V(药物与聚合物的比例为1:0.470)显示出的药物释放模式非常接近理论释放曲线。将动力学方程模型应用于F-V批料,发现其遵循Higuchi模型,因为该图显示出高线性,相关系数(R2)值为0.9911。因此,F-V片制剂显示出以扩散为主的药物释放。加速稳定性研究表明,保质期为40个月(批次F-V),并且药物的存储前景良好。简介醋氯芬酸是一种苯乙酸衍生物,是一种与双氯芬酸有关的非甾体类抗炎药(NSAID)。它用于治疗骨关节炎,类风湿关节炎和烷基化性脊柱炎(1)。醋氯芬酸具有镇痛和抗炎特性,可在多种疼痛情况下缓解症状。醋氯芬酸具有良好的耐受性,大多数不良反应较小且可逆,主要影响胃肠道系统(2)。口服给药后,它可以很好地从胃肠道吸收,血浆峰值浓度(Cmax)达到1-3小时。短的生物半衰期(约4.3小时)和对持续时间的需求有利于开发缓释制剂。缓释片剂可以提供诸如在治疗范围内限制波动,降低剂量频率和改善患者依从性等优势。延迟药物释放的最简单方法是将其分散在固体基质中。基质系统通常用于制造缓释剂型,特别是片剂,因为它使这种制造容易。配制药物的口服缓释(SR)时,亲水性基质是一种有趣的选择。基质装置的剂量释放特性可能取决于药物在聚合物基质中的溶解度,或者在多孔基质的情况下,取决于颗粒孔网络内储液中的溶解度(3)。羟丙基甲基纤维素(HPMC)是用于制备口服控制药物递送系统的主要亲水性载体(4)。在文献中已进行了大量研究,以研究HPMC基质以控制多种药物从基质中的释放,并试图预测药物释放动力学模型(5-9)。根据大多数这些模型,由于赋形剂在基质中的作用,认为扩散发生在药物的释放和异常释放中。口服非甾体抗炎药(包括醋氯芬酸)的主要抱怨之一是与使用它们有关的胃刺激。因此,肠溶性醋氯芬酸片是解决胃肠道刺激问题的有趣选择。本研究的目的是使用HPMC基质制备肠溶性缓释醋氯芬酸片,以检查其体外释放特性,预测醋氯芬酸从体内的释放行为。基质并阐明所制备制剂的保质期。为了阐明释放动力学,必须将药物释放数据拟合到合适的模型中。理解药物从亲水性基质释放的常用模型是第一位的

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号